Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer’s disease (AD). The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase ( h AChE), might represent a breakthrough in the quest for clinical efficacy. Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized. Among these hybrids, 2f showed the most promising profile as a nanomolar inhibitor on both h AChE (IC 50 = 6.5 nM) and h GSK-3β kinase activity (IC 50 = 66 nM). It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM. Western blot analysis revealed that compound 2f inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells. In vivo studies confirmed that 2f significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine. This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“AChE/GSK-3β inhibitors 48536 and 49,537 developed through a pharmacophore linkage strategy, exhibited promising results by significantly inhibiting tau hyperphosphorylation and ameliorating cognitive disorders in scopolamine-treated ICR mice.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [536]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Alzheimer disease therapy—moving from amyloid-β to tau
Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 471
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Neurogenesis and Alzheimer's disease: At the crossroads
Lazarov, O., & Marr, R. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.009 · Cited by 327
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
A walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
Amyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
The role of tau kinases in Alzheimer's disease.
Dolan, P. J., & Johnson, G. V. W. (2010) · PubMed · Cited by 231
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease
Maqbool, M., Mobashir, M., & Hoda, N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.018 · Cited by 227
Multitarget therapeutic strategies for Alzheimer’s disease
Gabr, M., & Ibrahim, M. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.245463 · Cited by 190
Organocatalytic Mitsunobu Reactions
But, T. Y. S., & Toy, P. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja063141v · Cited by 163
Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo
Morales-Garcia, J. A., Luna-Medina, R., Alonso-Gil, S., Sanz-SanCristobal, M., Palomo, V., Gil, C., Santos, A., Martinez, A., & Perez-Castillo, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300110c · Cited by 161
Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease
Romero, A., Cacabelos, R., Oset-Gasque, M. J., Samadi, A., & Marco-Contelles, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.017 · Cited by 158
Nepovimova, E., Uliassi, E., Korabecny, J., Peña-Altamira, L. E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 151
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Cai, Z., Zhao, Y., & Zhao, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512802455386 · Cited by 145
Sivaprakasam, P., Han, X., Civiello, R. L., Jacutin-Porte, S., Kish, K., Pokross, M. E., Lewis, H. A., Ahmed, N., Szapiel, N., Newitt, J. A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.046 · Cited by 135
Avila, J., Wandosell, F., & Hernández, F. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.40 · Cited by 129
Nepovimova, E., Korabecny, J., Dolezal, R., Babkova, K., Ondrejicek, A., Jun, D., Sepsova, V., Horova, A., Hrabinova, M., Soukup, O., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01325 · Cited by 128
A High Throughput Luminescent Assay for Glycogen Synthase Kinase-3 β Inhibitors
Baki, A., Bielik, A., Molnár, L., Szendrei, G., & Keserü, G. M. (2007) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2006.029 · Cited by 125
Blaikie, L., Kay, G., & Kong Thoo Lin, P. (2019) · MedChemComm · doi:10.1039/c9md00337a · Cited by 112
Hybrids: a new paradigm to treat Alzheimer’s disease
Singh, M., Kaur, M., Chadha, N., & Silakari, O. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9628-9 · Cited by 92
Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer’s Disease
Spilovska, K., Korabecny, J., Nepovimova, E., Dolezal, R., Mezeiova, E., Soukup, O., & Kuca, K. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026605666160927152728 · Cited by 84
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
Hartmann, S., & M??bius, H. J. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200303000-00003 · Cited by 83
The Relationship between Amyloid and Tau
Hardy, J. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:2:203 · Cited by 80
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Hartmann, S., & Möbius, H. J. (2003) · PubMed · doi:10.1097/01.yic.0000054279.38655.74 · Cited by 72
Synthesis and structure–activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors
Reichelt, A. F., Bailis, J. M., Bartberger, M. D., Yao, G., Shu, H., Kaller, M. R., Allen, J. G., Weidner, M. F., Keegan, K. S., & Dao, J. H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.013 · Cited by 35
Nontoxic and Neuroprotective β-Naphthotacrines for Alzheimer’s Disease
Esquivias-Pérez, M., Maalej, E., Romero, A., Chabchoub, F., Samadi, A., Marco, J. L., & Oset‐Gasque, M. J. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400138s · Cited by 34
Barré, A., Azzouz, R., Gembus, V., Papamicaël, C. A., & Levacher, V. (2019) · Molecules · doi:10.3390/molecules24071264 · Cited by 12
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Self-citationA walk through tau therapeutic strategies
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 290
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
“In this regard, many examples employing this route were reported, among others is the design of dual GSK‐3β and acetylcholinesterase inhibitors.(191) In addition, MTDLs might ameliorate the performance of BACE1 inhibitors and synergize the potential of the AD treatment.”
BackgroundMulti-target design strategies for the improved treatment of Alzheimer's disease
Zhang, P., Xu, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.020 · Cited by 212
“Jiang and co-workers [44] reported a novel series of hybrids, fused with tacrine (4) and compound 42 (GSK-3β inhibitor, IC50 = 1.”
Background
Metadata
- Authors
- Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P.
- Affiliations
- Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
- China Pharmaceutical University (CN)
- Nanjing University of Chinese Medicine (CN)
- Corresponding author
- Feng, Feng
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-02-09
- Volume
- 9
- Issue
- 3
- Pages
- 171-176
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC5846044
- OpenAlex
- W2786033877
- Cited by
- 122
- References
- 34
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 21 · 2023: 12 · 2022: 14 · 2021: 9 · 2020: 14 · 2019: 17 · 2018: 5
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education of the People's Republic of China (2015ZD009)
- Natural Science Foundation of Jiangsu Province (BK20140957)
- Government of Jiangsu Province
- National Natural Science Foundation of China (81373956, 81402851, 81573281)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- Alzheimer's disease, multi-target-directed ligands, GSK-3β inhibition, acetylcholinesterase inhibition, dual inhibitors, amyloid-beta aggregation, tau hyperphosphorylation, tacrine, scopolamine-induced cognitive impairment, hepatotoxicity, drug discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.